METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Drug attack on Tough-to-Treat breast cancer
Disease control Recruiting nowThis study is testing a new combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer. The main goals are to find the safest and most effective dose and to see if the combination can shrink tumors. The trial is for adu…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Yale trial aims to tame tough breast cancer with dual drug attack
Disease control Recruiting nowThis study is testing two different drug combinations for people with advanced triple-negative breast cancer that has worsened after one prior treatment. The goal is to see if adding a newer immunotherapy drug to an existing treatment is safe and can better control the cancer. Ab…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Tough-to-Treat breast cancer: study tests drug targeting metabolism
Disease control Recruiting nowThis study is testing whether adding an experimental drug called evexomostat (SDX-7320) to standard chemotherapy (eribulin) works better for people with advanced triple-negative breast cancer who also have metabolic issues like high blood sugar or obesity. About 55 participants w…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC